Search

Your search keyword '"CHUNILAL, Sanjeev"' showing total 154 results
Start Over Author "CHUNILAL, Sanjeev" Language english
154 results on '"CHUNILAL, Sanjeev"'

4. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

Author

Loualidi, Ab, Colak, Abdurrahim, Bezuidenhout, Abraham, Abdool-Carrim, Abu, Azeddine, Addala, Beyers, Adriaan, Dees, Adriaan, Mohamed, Ahmed, Aksoy, Ahmet, Abiko, Akihiko, Watanabe, Akinori, Krichell, Alan, Fernandez, Alberto Alfredo, Tosetto, Alberto, Khotuntsov, Alexey, Oropallo, Alisha, Slocombe, Alison, Kelly, Allan, Clark, Amanda, Gad, Amr, Arouni, Amy, Schmidt, Andor, Berni, Andrea, Kleiban, Andres Javier, Machowski, Andrew, Kazakov, Andrey, Galvez, Angel, Lockman, Ann, Falanga, Anna, Chauhan, Anoop, Riera-Mestre, Antoni, Mazzone, Antonino, D'Angelo, Armando, Herdy, Artur, Kato, Atsushi, Salem, Ayman Abd Elhamid Ebrahim Mahmoud, Husin, Azlan, Erdelyi, Barbara, Jacobson, Barry, Amann-Vesti, Beatrice, Battaloglu, Bektas, Wilson, Benedicte, Cosmi, Benilde, Francois, Bergmann Jean, Toufek, Berremeli, Hunt, Beverley, Natha, Bhavesh, Mustafa, Bisher, Kho, Bonnie Chi Shan, Carine, Boulon, Zidel, Brian, Dominique, Brisot, Christophe, Brousse, Trimarco, Bruno, Luo, Canhua, Cuneo, Carlos Alberto, Diaz, Carlos Jerjes Sanchez, Schwencke, Carsten, Cader, Cas, Yavuz, Celal, Zaidman, Cesar Javier, Lunn, Charles, Wu, Chau-Chung, Toh, Cheng Hock, Chiang, Chern-En, Elisa, Chevrier, Hsia, Chien-Hsun, Huang, Chien-Lung, Kwok, Chi-Hang Kevin, Wu, Chih-Cheng, Huang, Chi-Hung, Ward, Chris, Opitz, Christian, Jeanneret-Gris, Christina, Ha, Chung Yin, Huang, Chun-Yao, Bidi, Claude Luyeye, Smith, Clifford, Brauer, Cornelia, Lodigiani, Corrado, Francis, Couturaud, Wu, Cynthia, Staub, Daniel, Theodoro, Daniel, Poli, Daniela, Acevedo, David - Riesco, Adler, David, Jimenez, David, Keeling, David, Scott, David, Imberti, Davide, Creagh, Desmond, Helene, Desmurs-Clavel, Hagemann, Dirk, Le Roux, Dirk, Skowasch, Dirk, Belenky, Dmitry, Dorokhov, Dmitry, Petrov, Dmitry, Zateyshchikov, Dmitry, Prisco, Domenico, Møller, Dorthe, Kucera, Dusan, Esheiba, Ehab M., Panchenko, Elizaveta, Dominique, Elkouri, Dogan, Emre, Kubat, Emre, Diaz, Enrique Diaz, Tse, Eric Wai Choi, Yeo, Erik, Hashas, Erman, Grochenig, Ernst, Tiraferri, Eros, Blessing, Erwin, Michèle, Escande Orthlieb, Usandizaga, Esther, Porreca, Ettore, Ferroni, Fabian, Nicolas, Falvo, Ayala-Paredes, Félix, Koura, Firas, Henry, Fitjerald, Cosmi, Franco, Erdkamp, Frans, Kamalov, Gadel, Dalmau, Garcia-Bragado, Damien, Garrigues, Klein, Garry, Shah, Gaurand, Hollanders, Geert, Merli, Geno, Plassmann, Georg, Platt, George, Poirier, Germain, Sokurenko, German, Haddad, Ghassan, Ali, Gholam, Agnelli, Giancarlo, Gan, Gin Gin, Kaye-Eddie, Grace, Le Gal, Gregoire, Allen, Gregory, Esperón, Guillermo Antonio Llamas, Jean-Paul, Guillot, Gerofke, Hagen, Elali, Hallah, Burianova, Hana, Ohler, Hans-Juergen, Wang, Haofu, Darius, Harald, Gogia, Harinder S., Striekwold, Harry, Gibbs, Harry, Hasanoglu, Hatice, Turker, Hatice, Franow, Hendrik, Bounameaux, Henri, De Raedt, Herbert, Schroe, Herman, ElDin, Hesham Salah, Zidan, Hesham, Nakamura, Hiroaki, Kim, Ho Young, Lawall, Holger, Zhu, Hong, Tian, Hongyan, Yhim, Ho-Young, ten Cate, Hugo, Hwang, Hun Gyu, Shim, Hyeok, Kim, Igor, Libov, Igor, Sonkin, Igor, Suchkov, Igor, Song, Ik-Chan, Kiris, Ilker, Staroverov, Ilya, Looi, Irene, De La Azuela Tenorio, Isabel M., Savas, Ismail, Gordeev, Ivan, Podpera, Ivo, Lee, Jae Hoon, Sathar, Jameela, Welker, James, Beyer-Westendorf, Jan, Kvasnicka, Jan, Vanwelden, Jan, Kim, JangYong, Svobodova, Jaromira, Gujral, Jaspal, Marino, Javier, Galvar, Javier Tristan, Kassis, Jeannine, Kuo, Jen-Yuan, Shih, Jhih-Yuan, Kwon, JiHyun, Joh, Jin Hyun, Park, Jin Hyun, Kim, Jin Seok, Yang, Jinghua, Krupicka, Jiri, Lastuvka, Jiri, Pumprla, Jiri, Vesely, Jiri, Souto, Joan Carlos, Correa, João Antônio, Duchateau, Johan, Fletcher, John Perry, del Toro, Jorge, Paez, Jorge Guillermo Chavez, Nielsen, Jørn, Filho, Jose Dalmo Araujo, Saraiva, Jose, Peromingo, Jose Antonio Diaz, Lara, Jose Gomez, Fedele, Jose Luis, Surinach, Jose Maria, Chacko, Joseph, Muntaner, Juan Antonio, Benitez, Juan Carlos Álvarez, Abril, Juan Moreno Hoyos, Humphrey, Julian, Bono, Julio, Kanda, Junji, Boondumrongsagoon, Juree, Yiu, Kai Hang, Chansung, Kanchana, Boomars, Karin, Burbury, Kate, Kondo, Katsuhiro, Karaarslan, Kemal, Takeuchi, Kensuke, Kroeger, Knut, Zrazhevskiy, Konstantin, Svatopluk, Koscál, Shyu, Kou-Gi, Vandenbosch, Kristel, Chang, Kuan-Cheng, Chiu, Kuan-Ming, Jean-Manuel, Kubina, Wern, Kwan Jing, Ueng, Kwo-Chang, Norasetthada, Lalita, Binet, Laure, Chew, Lee Ping, Zhang, Lei, Cristina, Leone Maria, Tick, Lidwine, Schiavi, Lilia Beatriz, Wong, Lily Lee Lee, Borges, Lohana, Botha, Louis, Capiau, Luc, Timmermans, Luc, López, Luciano Eduardo, Ria, Luigi, Blasco, Luis Manuel Hernandez, Guzman, Luis Alberto, Cervera, Luis Flota, Isabelle, Mahe, Bosch, Manuel Monreal, de los Rios Ibarra, Manuel, Fernandez, Manuel Núñez, Carrier, Marc, Barrionuevo, Marcelo Raul, Gamba, Marco Antonio Alcocer, Cattaneo, Marco, Moia, Marco, Bowers, Margaret, Chetanachan, Mariam, Berli, Mario Alberto, Fixley, Mark, Faghih, Markus, Stuecker, Markus, Schul, Marlin, Banyai, Martin, Koretzky, Martin, Myriam, Martin, Gaffney, Mary Elizabeth, Hirano, Masao, Kanemoto, Masashi, Nakamura, Mashio, Tahar, Mersel, Emmanuel, Messas, Kovacs, Michael, Leahy, Michael, Levy, Michael, Munch, Michael, Olsen, Michael, De Pauw, Michel, Gustin, Michel, Van Betsbrugge, Michiel, Boyarkin, Mikhail, Homza, Miroslav, Koto, Modise, Abdool-Gaffar, Mohamed, Nagib, Mohamed Ayman Fakhry, El-Dessoki, Mohamed, Khan, Mohamed, Mohamed, Monniaty, Kim, Moo Hyun, Lee, Moon-Hee, Soliman, Mosaad, Ahmed, Mostafa Shawky, el Bary, Mostafa Soliman Abd, Moustafa, Moustafa A., Hameed, Muhammad, Kanko, Muhip, Majumder, Mujibur, Zubareva, Nadezhda, Mumoli, Nicola, Abdullah, Nik Azim Nik, Makruasi, Nisa, Paruk, Nishen, Kanitsap, Nonglak, Duda, Norberto, Nordin, Nordiana, Nyvad, Ole, Barbarash, Olga, Gurbuz, Orcun, Vilamajo, Oscar Gomez, Flores, Oscar Nandayapa, Gur, Ozcan, Oto, Oztekin, Marchena, Pablo Javier, Angchaisuksiri, Pantep, Carroll, Patrick, Lang, Pavel, MacCallum, Peter, von Bilderling, Peter Baron, Blombery, Peter, Verhamme, Peter, Jansky, Petr, Bernadette, Peuch, De Vleeschauwer, Philippe, Hainaut, Philippe, Ferrini, Piera Maria, Iamsai, Piriyaporn, Christian, Ponchaux, Viboonjuntra, Pongtep, Rojnuckarin, Ponlapat, Ho, Prahlad, Mutirangura, Pramook, Wells, Rachel, Martinez, Rafael, Miranda, Raimundo Tirado, Kroening, Ralf, Ratsela, Rapule, Reyes, Raquel Lopez, de Leon, Raul Franco Diaz, Wong, Raymond Siu Ming, Alikhan, Raz, Jerwan-Keim, Reinhold, Otero, Remedios, Murena-Schmidt, Renate, Canevascini, Reto, Ferkl, Richard, White, Richard, Van Herreweghe, Rika, Santoro, Rita, Klamroth, Robert, Mendes, Robert, Prosecky, Robert, Cappelli, Roberto, Spacek, Rudolf, Singh, Rupesh, Griffin, Sam, Na, Sang Hoon, Chunilal, Sanjeev, Middeldorp, Saskia, Nakazawa, Satoshi, Schellong, Sebastian, Toh, See Guan, Christophe, Seinturier, Isbir, Selim, Raymundo, Selma, Ting, Seng Kiat, Motte, Serge, Aktogu, Serir Ozkan, Donders, Servaas, Cha, Seung Ick, Nam, Seung-Hyun, Marie-Antoinette, Sevestre-Pietri, Maasdorp, Shaun, Sun, Shenghua, Wang, Shenming, Essameldin, Sherif Mohamed, Sholkamy, Sherif Mohamed, Kuki, Shintaro, Goto, Shinya, Yoshida, Shuichi, Matsuoka, Shunzo, McRae, Simon, Watt, Simon, Patanasing, Siriwimon, Jean-Léopold, Siwe-Nana, Wongkhantee, Somchai, Bang, Soo-Mee, Testa, Sophie, Zemek, Stanislav, Behrens, Steffen, Dominique, Stephan, Mellor, Stuart, Singh, Suaran Singh Gurcharan, Datta, Sudip, Chayangsu, Sunee, Solymoss, Susan, Everington, Tamara, Abdel-Azim, Tarek Ahmed Adel, Suwanban, Tawatchai, Adademir, Taylan, Hart, Terence, Béatrice, Terriat, Luvhengo, Thifhelimbilu, Horacek, Thomas, Zeller, Thomas, Boussy, Tim, Reynolds, Tim, Biss, Tina, Chao, Ting-Hsing, Casabella, Tomas Smith, Onodera, Tomoya, Numbenjapon, Tontanai, Gerdes, Victor, Cech, Vladimir, Krasavin, Vladimir, Tolstikhin, Vladimir, Bax, W.A., Malek, Wagih Fawzy Abdel, Ho, Wai Khoon, Ageno, Walter, Pharr, Walter, Jiang, Weihong, Lin, Wei-Hsiang, Zhang, Weihua, Tseng, Wei-Kung, Lai, Wen-Ter, De Backer, Wilfried, Haverkamp, Wilhelm, Yoshida, Winston, Korte, Wolfgang, Choi, Won Il, Kim, Yang-Ki, Tanabe, Yasuhiro, Ohnuma, Yasushi, Mun, Yeung-Chul, Balthazar, Yohan, Park, Yong, Shibata, Yoshisato, Burov, Yuriy, Subbotin, Yuriy, Coufal, Zdenek, Yang, Zhenwen, Jing, Zhicheng, Yang, Zhongqi, Turpie, Alexander G.G., Farjat, Alfredo E., Haas, Sylvia, Weitz, Jeffrey I., Goldhaber, Samuel Z., Kayani, Gloria, Lopes, Renato D., Tse, Eric, Muntaner, Juan, Prandoni, Paolo, Maheshwari, Uma, and Kakkar, Ajay K.

Published
2023
Full Text
View/download PDF

5. Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients

Author

Favaloro, Emmanuel J., Clifford, Joanne, Leitinger, Emma, Parker, Michael, Sung, Pauline, Chunilal, Sanjeev, Tran, Huyen, Kershaw, Geoffrey, Fu, Suki, Passam, Freda, Ahuja, Monica, Ho, Shir Jing, Duncan, Elizabeth, Yacoub, Olivia, Tan, Chee Wee, Kaminskis, Lisa, Modica, Natasha, Pepperell, Dominic, Ballard, Leanne, Clarke, Lisa, Lee, Christine S.M., Gardiner, Elizabeth E., Young‐Ill Choi, Philip, Tohidi‐Esfahani, Ibrahim, Bird, Robert, Brighton, Timothy, and Chen, Vivien M.

Published
2022
Full Text
View/download PDF

8. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

Author

Haas, Sylvia, Ageno, Walter, Weitz, Jeffrey I., Goldhaber, Samuel Z., Turpie, Alexander G.G., Goto, Shinya, Angchaisuksiri, Pantep, Dalsgaard Nielsen, Joern, Kayani, Gloria, Zaghdoun, Audrey, Farjat, Alfredo E., Schellong, Sebastian, Bounameaux, Henri, Mantovani, Lorenzo G., Prandoni, Paolo, Kakkar, Ajay K., Loualidi, Ab, Colak, Abdurrahim, Bezuidenhout, Abraham, Abdool‐Carrim, Abu, Azeddine, Addala, Beyers, Adriaan, Dees, Adriaan, Mohamed, Ahmed, Aksoy, Ahmet, Abiko, Akihiko, Watanabe, Akinori, Krichell, Alan, Fernandez, Alberto Alfredo, Tosetto, Alberto, Khotuntsov, Alexey, Oropallo, Alisha, Slocombe, Alison, Kelly, Allan, Clark, Amanda, Gad, Amr, Arouni, Amy, Schmidt, Andor, Berni, Andrea, Kleiban, Andres Javier, Machowski, Andrew, Kazakov, Andrey, Galvez, Angel, Lockman, Ann, Falanga, Anna, Chauhan, Anoop, Riera‐Mestre, Antoni, Mazzone, Antonino, D'Angelo, Armando, Herdy, Artur, Kato, Atsushi, Ebrahim, Ayman Abd Elhamid, Salem, Mahmoud, Husin, Azlan, Erdelyi, Barbara, Jacobson, Barry, Amann‐Vesti, Beatrice, Battaloglu, Bektas, Wilson, Benedicte, Cosmi, Benilde, Francois, Bergmann Jean, Toufek, Berremeli, Hunt, Beverley, Natha, Bhavesh, Mustafa, Bisher, Kho, Bonnie Chi Shan, Carine, Boulon, Zidel, Brian, Dominique, Brisot, Christophe, Brousse, Trimarco, Bruno, Luo, Canhua, Alberto Cuneo, Carlos, Sanchez Diaz, Carlos Jerjes, Schwencke, Carsten, Cader, Cas, Yavuz, Celal, Javier Zaidman, Cesar, Lunn, Charles, Wu, Chau‐Chung, Toh, Cheng Hock, Chiang, Chern‐En, Elisa, Chevrier, Hsia, Chien‐Hsun, Huang, Chien‐Lung, Kwok, Chi‐Hang Kevin, Wu, Chih‐Cheng, Huang, Chi‐Hung, Ward, Chris, Opitz, Christian, Jeanneret‐Gris, Christina, Ha, Chung Yin, Huang, Chun‐Yao, Bidi, Claude Luyeye, Smith, Clifford, Brauer, Cornelia, Lodigiani, Corrado, Francis, Couturaud, Wu, Cynthia, Staub, Daniel, Theodoro, Daniel, Poli, Daniela, Acevedo, Riesco, Adler, David, Jimenez, David, Keeling, David, Scott, David, Imberti, Davide, Creagh, Desmond, Helene, Desmurs‐Clavel, Hagemann, Dirk, Le Roux, Dirk, Skowasch, Dirk, Belenky, Dmitry, Dorokhov, Dmitry, Petrov, Dmitry, Zateyshchikov, Dmitry, Prisco, Domenico, Møller, Dorthe, Kucera, Dusan, Esheiba, Ehab M., Panchenko, Elizaveta, Dominique, Elkouri, Dogan, Emre, Kubat, Emre, Diaz Diaz, Enrique, Tse, Eric Wai Choi, Yeo, Erik, Hashas, Erman, Grochenig, Ernst, Tiraferri, Eros, Blessing, Erwin, Michèle, Escande Orthlieb, Usandizaga, Esther, Porreca, Ettore, Ferroni, Fabian, Nicolas, Falvo, Ayala‐Paredes, Félix, Koura, Firas, Henry, Fitjerald, Cosmi, Franco, Erdkamp, Frans, Kamalov, Gadel, Dalmau, Garcia‐Bragado, Damien, Garrigues, Klein, Garry, Shah, Gaurand, Hollanders, Geert, Merli, Geno, Plassmann, Georg, Platt, George, Poirier, Germain, Sokurenko, German, Haddad, Ghassan, Ali, Gholam, Agnelli, Giancarlo, Gan, Gin Gin, Kaye‐Eddie, Grace, Le Gal, Gregoire, Allen, Gregory, Llamas Esperón, Guillermo Antonio, Jean‐Paul, Guillot, Gerofke, Hagen, Elali, Hallah, Burianova, Hana, Ohler, Hans‐Juergen, Wang, Haofu, Darius, Harald, Gogia, Harinder S., Striekwold, Harry, Gibbs, Harry, Hasanoglu, Hatice, Turker, Hatice, Franow, Hendrik, De Raedt, Herbert, Schroe, Herman, ElDin, Hesham Salah, Zidan, Hesham, Nakamura, Hiroaki, Kim, Ho Young, Lawall, Holger, Zhu, Hong, Tian, Hongyan, Yhim, Ho‐Young, ten Cate, Hugo, Hwang, Hun Gyu, Shim, Hyeok, Kim, Igor, Libov, Igor, Sonkin, Igor, Suchkov, Igor, Song, Ik‐Chan, Kiris, Ilker, Staroverov, Ilya, Looi, Irene, De La Azuela Tenorio, Isabel M, Savas, Ismail, Gordeev, Ivan, Podpera, Ivo, Lee, Jae Hoon, Sathar, Jameela, Welker, James, Beyer‐Westendorf, Jan, Kvasnicka, Jan, Vanwelden, Jan, Kim, JangYong, Svobodova, Jaromira, Gujral, Jaspal, Marino, Javier, Galvar, Javier Tristan, Kassis, Jeannine, Kuo, Jen‐Yuan, Shih, Jhih‐Yuan, Kwon, JiHyun, Joh, Jin Hyun, Park, Jin Hyun, Kim, Jin Seok, Yang, Jinghua, Krupicka, Jiri, Lastuvka, Jiri, Pumprla, Jiri, Vesely, Jiri, Carlos Souto, Joan, Antônio Correa, João, Duchateau, Johan, Fletcher, John Perry, del Toro, Jorge, Chavez Paez, Jorge Guillermo, Araujo Filho, Jose Dalmo, Saraiva, Jose, Diaz Peromingo, Jose Antonio, Gomez Lara, Jose, Luis Fedele, Jose, Maria Surinach, Jose, Chacko, Joseph, Antonio Muntaner, Juan, Álvarez Benitez, Juan Carlos, Hoyos Abril, Juan Moreno, Humphrey, Julian, Bono, Julio, Kanda, Junji, Boondumrongsagoon, Juree, Yiu, Kai Hang, Chansung, Kanchana, Boomars, Karin, Burbury, Kate, Kondo, Katsuhiro, Karaarslan, Kemal, Takeuchi, Kensuke, Kroeger, Knut, Zrazhevskiy, Konstantin, Svatopluk, Koscál, Shyu, Kou‐Gi, Vandenbosch, Kristel, Chang, Kuan‐Cheng, Chiu, Kuan‐Ming, Jean‐Manuel, Kubina, Wern, Kwan Jing, Ueng, Kwo‐Chang, Norasetthada, Lalita, Binet, Laure, Chew, Lee Ping, Zhang, Lei, Cristina, Leone Maria, Tick, Lidwine, Beatriz Schiavi, Lilia, Wong, Lily Lee Lee, Borges, Lohana, Botha, Louis, Capiau, Luc, Timmermans, Luc, Eduardo López, Luciano, Ria, Luigi, Hernandez Blasco, Luis Manuel, Guzman, Luis Alberto, Flota Cervera, Luis, Isabelle, Mahe, Monreal Bosch, Manuel, de los Rios Ibarra, Manuel, Núñez Fernandez, Manuel, Carrier, Marc, Raul Barrionuevo, Marcelo, Alcocer Gamba, Marco Antonio, Cattaneo, Marco, Moia, Marco, Bowers, Margaret, Chetanachan, Mariam, Berli, Mario Alberto, Fixley, Mark, Faghih, Markus, Stuecker, Markus, Schul, Marlin, Banyai, Martin, Koretzky, Martin, Myriam, Martin, Gaffney, Mary Elizabeth, Hirano, Masao, Kanemoto, Masashi, Nakamura, Mashio, Tahar, Mersel, Emmanuel, Messas, Kovacs, Michael, Leahy, Michael, Levy, Michael, Munch, Michael, Olsen, Michael, De Pauw, Michel, Gustin, Michel, Van Betsbrugge, Michiel, Boyarkin, Mikhail, Homza, Miroslav, Koto, Modise, Abdool‐Gaffar, Mohamed, Nagib, Mohamed Ayman Fakhry, El‐Dessoki, Mohamed, Khan, Mohamed, Mohamed, Monniaty, Kim, Moo Hyun, Lee, Moon‐Hee, Soliman, Mosaad, Ahmed, Mostafa Shawky, el Bary, Mostafa Soliman Abd, Moustafa, Moustafa A., Hameed, Muhammad, Kanko, Muhip, Majumder, Mujibur, Zubareva, Nadezhda, Mumoli, Nicola, Abdullah, Nik Azim Nik, Makruasi, Nisa, Paruk, Nishen, Kanitsap, Nonglak, Duda, Norberto, Nordin, Nordiana, Nyvad, Ole, Barbarash, Olga, Gurbuz, Orcun, Vilamajo, Oscar Gomez, Nandayapa Flores, Oscar, Gur, Ozcan, Oto, Oztekin, Javier Marchena, Pablo, Carroll, Patrick, Lang, Pavel, MacCallum, Peter, von Bilderling, Peter Baron, Blombery, Peter, Verhamme, Peter, Jansky, Petr, Bernadette, Peuch, De Vleeschauwer, Philippe, Hainaut, Philippe, Ferrini, Piera Maria, Iamsai, Piriyaporn, Christian, Ponchaux, Viboonjuntra, Pongtep, Rojnuckarin, Ponlapat, Ho, Prahlad, Mutirangura, Pramook, Wells, Rachel, Martinez, Rafael, Miranda, Raimundo Tirado, Kroening, Ralf, Ratsela, Rapule, Reyes, Raquel Lopez, Diaz de Leon, Raul Franco, Wong, Raymond Siu Ming, Alikhan, Raz, Jerwan‐Keim, Reinhold, Otero, Remedios, Murena‐Schmidt, Renate, Canevascini, Reto, Ferkl, Richard, White, Richard, Van Herreweghe, Rika, Santoro, Rita, Klamroth, Robert, Mendes, Robert, Prosecky, Robert, Cappelli, Roberto, Spacek, Rudolf, Singh, Rupesh, Griffin, Sam, Na, Sang Hoon, Chunilal, Sanjeev, Middeldorp, Saskia, Nakazawa, Satoshi, Toh, See Guan, Christophe, Seinturier, Isbir, Selim, Raymundo, Selma, Ting, Seng Kiat, Motte, Serge, Aktogu, Serir Ozkan, Donders, Servaas, Cha, Seung Ick, Nam, Seung‐Hyun, Marie‐Antoinette, Sevestre‐Pietri, Maasdorp, Shaun, Sun, Shenghua, Wang, Shenming, Essameldin, Sherif Mohamed, Sholkamy, Sherif Mohamed, Kuki, Shintaro, Yoshida, Shuichi, Matsuoka, Shunzo, McRae, Simon, Watt, Simon, Patanasing, Siriwimon, Jean‐Léopold, Siwe‐Nana, Wongkhantee, Somchai, Bang, Soo‐Mee, Testa, Sophie, Zemek, Stanislav, Behrens, Steffen, Dominique, Stephan, Mellor, Stuart, Singh, Suaran Singh Gurcharan, Datta, Sudip, Chayangsu, Sunee, Solymoss, Susan, Everington, Tamara, Abdel‐Azim, Tarek Ahmed Adel, Suwanban, Tawatchai, Adademir, Taylan, Hart, Terence, Béatrice, Terriat, Luvhengo, Thifhelimbilu, Horacek, Thomas, Zeller, Thomas, Boussy, Tim, Reynolds, Tim, Biss, Tina, Chao, Ting‐Hsing, Casabella, Tomas Smith, Onodera, Tomoya, Numbenjapon, Tontanai, Gerdes, Victor, Cech, Vladimir, Krasavin, Vladimir, Tolstikhin, Vladimir, Bax, W.A., Malek, Wagih Fawzy Abdel, Ho, Wai Khoon, Pharr, Walter, Jiang, Weihong, Lin, Wei‐Hsiang, Zhang, Weihua, Tseng, Wei‐Kung, Lai, Wen‐Ter, De Backer, Wilfried, Haverkamp, Wilhelm, Yoshida, Winston, Korte, Wolfgang, Choi, Won II, Kim, Yang‐Ki, Tanabe, Yasuhiro, Ohnuma, Yasushi, Mun, Yeung‐Chul, Balthazar, Yohan, Park, Yong, Shibata, Yoshisato, Burov, Yuriy, Subbotin, Yuriy, Coufal, Zdenek, Yang, Zhenwen, Jing, Zhicheng, and Yang, Zhongqi

Published
2019
Full Text
View/download PDF

11. Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Author

McQuilten, Zoe, Venkatesh, Balasubramanian, Jha, Vivekanand, Roberts, Jason, Morpeth, Susan, Totterdell, James, McPhee, Grace, Abraham, John, Bam, Niraj, Bandara, Methma, Bangi, Ashpak, Barina, Lauren, Basnet, Bhupendra, Bhally, Hasan, Bhusal, Khemr, Bogati, Umesh, Bowen, Asha, Burke, Andrew, Christopher, Devasahayam, Chunilal, Sanjeev, Cochrane, Belinda, Curnow, Jennifer, Dara Reddy, Varaprasad Babu, Das, Santa, Dhungana, Ashesh, Di Tanna, Gian Luca, Dotel, Ravindra, DSouza, Hyjel, Dummer, Jack, Dutta, Sourabh, Foo, Hong, Gilbey, Timothy, Giles, Michelle, Goli, Kasiram, Gordon, Adrienne, Gyanwali, Pradip, Hudson, Bernard, Jani, Manoj, Jevaji, Purnima, Jhawar, Sachin, Jindal, Aikaj, John, M. Joseph, John, Mary, John, Flavita, John, Oommen, Jones, Mark, Joshi, Rajesh, Kamath, Prashanthi, Kang, Gagandeep, Karki, Achyut, Karmalkar, Abhishek, Kaur, Baldeep, Koganti, Kalyan Chakravarthy, Koshy, Jency, Mathew, S K, Lau, Jilllian, Lewin, Sharon, Lim, Lyn-li, Marschner, Ian, Marsh, Julie, Maze, Michael, McGree, James, McMahon, James, Medcalf, Robert, Merriman, Eileen, Misal, Amol, Mora, Jocelyn, Mudaliar, Vijaybabu, Nguyen, Vi, O'Sullivan, Matthew, Pant, Suman, Pant, Pankaj, Paterson, David, Price, David, Rees, Megan, Robinson, James Owen, Rogers, Benjamin, Samuel, Sandhya, Sasadeusz, Joe, Sharma, Deepak, Sharma, Prabhat, Shrestha, Roshan, Shrestha, Sailesh, Shrestha, Prajowl, Shukla, Urvi, Shum, Omar, Sommerville, Christine, Spelman, Tim, Sullivan, Richard, Thatavarthi, Umashankar, Tran, Huyen, Trask, Nanette, Whitehead, Claire, Mahar, Robert, Hammond, Naomi, McFadyen, James David, Snelling, Thomas, Davis, Joshua, Denholm, Justin, and Tong, Steven YC

Published
2022
Full Text
View/download PDF

12. Central venous access device practice across haematology and oncology centres in Australia and New Zealand: a cross‐sectional survey.

Author

Yuen, Hiu L. A., Weinkove, Robert, Ullman, Amanda, Marsh, Nicole, Rickard, Claire M., Chunilal, Sanjeev, and McQuilten, Zoe

Subjects
SPECIALTY hospitals, MEDICAL device removal, CENTRAL venous catheterization, HEMATOLOGY, CROSS-sectional method, CANCER treatment, CATHETERIZATION complications, RESEARCH funding, QUESTIONNAIRES, CATHETERIZATION
Abstract

Central venous access devices (CVADs) are commonly used in malignancies. We conducted an online, anonymous cross‐sectional survey of practice regarding CVAD management in haematology centres among clinicians in Australia and New Zealand. We identified variation in clinical practice regarding CVAD selection, insertion, management and removal. These findings highlight research gaps in CVAD care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Idiopathic upper extremity deep vein thrombosis: A systematic review.

Author

Yuen, Hiu Lam Agnes, Tan, Ee, Tran, Huyen, and Chunilal, Sanjeev Daya

Subjects
VENOUS thrombosis, FORELIMB, THROMBOLYTIC therapy, POSTTHROMBOTIC syndrome, THROMBOEMBOLISM, ORAL contraceptives
Abstract

Background: Idiopathic upper extremity deep vein thrombosis (UEDVT) management is controversial and ranges from anticoagulation alone to the addition of further interventions such as thrombolysis and decompressive surgery. Objectives: The objective of this systematic review was to assess the effects of anticoagulation alone compared to anticoagulation with additional interventions such as thrombolysis or decompressive surgery on the incidence of recurrent UEDVT and post‐thrombotic syndrome (PTS) in patients with idiopathic UEDVT (including those associated with the oral contraceptive pill). Patients/Methods: A systematic search was conducted for studies which focused on acute UEDVT treatment defined as therapies starting within 4 weeks of symptom onset. We limited studies to those that recruited 10 or more subjects and involved at least 6 weeks to 12 months anticoagulation alone or together with additional interventions with at least 6‐month follow‐up. Primary outcomes were symptomatic recurrent radiologically confirmed UEDVT and PTS. Secondary outcomes were symptomatic venous thromboembolism, bleeding and mortality. Results: We found seven studies which reported recurrent UEDVT rates and five that reported PTS rates. All studies were retrospective or cross‐sectional. None compared anticoagulation alone to anticoagulation with additional intervention. Study heterogeneity precluded meta‐analysis and risk of bias was moderate to serious. Recurrent UEDVT occurred in 0% to 12% post‐anticoagulation alone and 0% to 23% post‐additional interventions. PTS rates varied from 4% to 32% without severe PTS. Only limited studies reported on our secondary outcomes. Conclusion: There is limited evidence behind idiopathic UEDVT management. Prospective comparative studies in this area are essential. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Does this patient have pulmonary embolism?

Author

Chunilal, Sanjeev D., Eikelboom, John W., Attia, John, Miniati, Massimo, Panju, Akbar A., Simel, David L., and Ginsberg, Jeffrey S.

Subjects
Algorithm, Algorithms -- Evaluation, Pulmonary embolism -- Diagnosis
Abstract

Clinical prediction rules can be used to determine if a particular patient has a low, moderate, or high risk of having a pulmonary embolism, according to researchers who analyzed 16 studies covering 8,306 patients. Clinical prediction rules are a type of algorithm that are used to identify patients with a particular medical condition based on signs and symptoms. Pulmonary embolism occurs when a blood clot forms in the legs and travels to the lungs.

Published
2003

21. Understanding vaccine‐induced thrombotic thrombocytopenia (VITT).

Author

Dix, Caroline, McFadyen, James, Huang, Angela, Chunilal, Sanjeev, Chen, Vivien, and Tran, Huyen

Subjects
THROMBOSIS, IMMUNIZATION, COVID-19 vaccines, DISEASES, THROMBOCYTOPENIA, SYMPTOMS
Abstract

Vaccine‐induced thrombotic thrombocytopenia (VITT) is a rare, but serious, syndrome characterised by thrombocytopenia, thrombosis, a markedly raised D‐dimer and the presence of anti‐platelet factor‐4 (PF4) antibodies following COVID‐19 adenovirus vector vaccination. VITT occurs at a rate of approximately 2 per 100 000 first‐dose vaccinations and appears exceedingly rare following second doses. Our current understanding of VITT pathogenesis is based on the observations that patients with VITT have antibodies that bind to PF4 and have the ability to form immune complexes that induce potent platelet activation. However, the precise mechanisms that lead to pathogenic VITT antibody development remain a source of active investigation. Thrombosis in VITT can manifest in any vascular bed and affect multiple sites simultaneously. While there is a predilection for splanchnic and cerebral venous sinus thrombosis, VITT also commonly presents with deep vein thrombosis and pulmonary embolism. Pillars of management include anticoagulation with a non‐heparin anticoagulant, intravenous immunoglobulin and 'rescue' therapies, such as plasma exchange for severe cases. VITT can be associated with a high mortality rate and significant morbidity, but awareness and optimal therapy have significantly improved outcomes in Australia. A number of questions remain unanswered, including why VITT is so rare, reasons for the predilection for thrombosis in unusual sites, how long pathological antibodies persist, and the optimal duration of anticoagulation. This review will provide an overview of the presentation, diagnostic workup and management strategies for patients with VITT. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Cannula provoked upper extremity superficial vein thrombophlebitis: are we overtreating?

Author

Yuen, Hiu L. A., Fang, Wendy, Tran, Huyen, and Chunilal, Sanjeev D.

Subjects
CONFIDENCE intervals, ARM, VENOUS thrombosis, DESCRIPTIVE statistics, THROMBOPHLEBITIS, CATHETERS
Abstract

Cannula provoked upper extremity superficial vein thrombophlebitis (UESVT) is common. Retrospective audit of 93 consecutive patients, 51% male, median age 57 years (range 20–91), with symptomatic UESVT revealed varied management including symptomatic management (37%), prophylactic (37%) and higher dose anticoagulation (27%). There was 2% (95% confidence interval (CI) 0–7.6) thrombus extension and 1% (95% CI 0–5.9) major bleeding, both limited to cancer. We argue anticoagulation is unnecessary in most UESVT patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER study).

Author

Merriman, Eileen, Chunilal, Sanjeev, Brighton, Tim, Chen, Vivien, McRae, Simon, Ockelford, Paul, Curnow, Jennifer, Tran, Huy, Chong, Beng, Smith, Mark, Royle, Gordon, Crowther, Helen, Slocombe, Alison, and Tran, Huyen

Subjects
*LOW-molecular-weight heparin, *VENOUS thrombosis, *THROMBOSIS, *THROMBOEMBOLISM, *POSTTHROMBOTIC syndrome
Abstract

Treatment of low-risk patients with isolated symptomatic distal deep vein thrombi (IDDVT) is uncertain. Objective: assess whether two weeks of therapeutic anticoagulation is efficacious/safe for IDDVT. Primary outcome: symptomatic three-month venous thromboembolism (VTE) incidence in the two-week anticoagulation group. Secondary outcomes included post-thrombotic syndrome (PTS) and bleeding. Prospective multicentre cohort study. Consecutive low-risk IDDVT patients enrolled within 72 h of diagnosis and treated with therapeutic dose enoxaparin or rivaroxaban. At two weeks, patients had repeat complete whole leg compression ultrasound (CUS)/clinical review. If resolution of leg symptoms AND no radiological evidence of thrombus extension, anticoagulation was stopped. If ongoing symptoms and/or radiographic extension within distal veins, anticoagulation was continued for four more weeks. Patients with extension into the popliteal vein on two-week ultrasound were treated off-study. Patients were reviewed at three and six months. 241 eligible patients received ≥2 weeks anticoagulation. 167/241 (69%) were assigned to the 2-week anticoagulation group; 71/241 (30%) to the six-week anticoagulation group; 3/241 patients (1%) had extension into the popliteal vein on two-week CUS. Two patients in the two-week anticoagulation group had symptomatic IDDVT recurrence in ≤3 months; VTE recurrence 2/156; 1.3%(95% CI 0.05–4.85%). 69% of patients had complete resolution of symptoms within two weeks. Six-month PTS rates were 8/184, 4.4%(95% CI 2.1–8.5%). No major bleeding was reported. Our findings suggest it's safe/efficacious to stop therapeutic anticoagulation at two weeks in low-risk IDDVT patients with resolution of symptoms/no extension on ultrasound. This could replace 6–12 weeks of anticoagulation for ambulatory, low-risk IDDVT patients. ClinicalTrials.gov NCT01252420 • The optimal treatment for isolated distal deep vein deep vein thrombosis (IDDVT) is uncertain. • This was a multicentre prospective cohort study enrolling consecutive patients with IDDVT. • Two weeks of anticoagulation achieved symptomatic relief in the majority of patients with low-risk IDDVT (69%). • Two weeks of anticoagulation was associated with a low risk of recurrent venous thromboembolism (VTE); 1.3%. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Upper Extremity Deep Vein Thrombosis: Current Knowledge and Future Directions.

Author

Yuen, Hiu Lam Agnes, Tran, Huyen, and Chunilal, Sanjeev

Subjects
VENOUS thrombosis, PERIPHERALLY inserted central catheters, THORACIC outlet syndrome, FORELIMB, CENTRAL venous catheters
Abstract

Upper extremity deep vein thrombosis (UEDVT) has been increasing in incidence due to the escalating use of central venous catheters such as peripherally inserted central catheters. UEDVT can be primary idiopathic or secondary to pacemaker leads, intravascular catheters or cancer. In comparison to conventional venous thromboembolism such as lower limb deep vein thrombosis or pulmonary embolism the risk factors, investigations, and management are not well defined. We review current evidence in primary and secondary UEDVT, highlighting areas in need of further research. We also explore the entity of venous thoracic outlet syndrome, which is said to be a risk factor for recurrent primary UEDVT and is the rationale behind surgical interventions. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. Safety of rapid injection of undiluted ferric carboxymaltose to patients with iron‐deficiency anaemia: a Phase II single‐arm study.

Author

Pasricha, Sant‐Rayn, Gilbertson, Michael, Indran, Tishya, Bennett, Ashwini, van Dam, Matthew, Coughlin, Elizabeth, Dev, Anouk, Chunilal, Sanjeev, and Opat, Stephen

Subjects
BLOOD serum analysis, HEMOGLOBINS, DRUG tolerance, OUTPATIENT medical care, INTRAVENOUS therapy, IRON, BLOOD collection, RISK assessment, IRON deficiency anemia, INTRAVENOUS injections, IRON regulatory proteins, HEADACHE, PATIENT safety, IRON compounds, PHOSPHATES
Abstract

Background: Ferric carboxymaltose is increasingly utilised to treat iron deficiency and is usually diluted in saline and administered as an intravenous infusion over 15 min. Although this is highly convenient compared with older formulations, we hypothesised the drug could be administered, safely given as a rapid bolus injection. Aims: To define the risk of serious adverse events following administration of an undiluted, rapid, high‐dose ferric carboxymaltose injection. Secondary aims included all other adverse events, as well as longitudinal effects on haemoglobin, iron stores, phosphate and hepcidin. Methods: In a single‐arm, Phase II study in 121 patients with iron‐deficiency anaemia, we administered up to 1000 mg of ferric carboxymaltose as a rapid undiluted bolus injection, and recorded adverse events and collected blood samples over the first hour, and again at 2 and 4 weeks post‐treatment. Results: No patient experienced a serious adverse event. Flushing during the injection was common, as was a transient headache in the subsequent weeks. One patient experienced Grade 3 chest tightness, necessitating emergency department assessment but not admission or treatment. Treatment produced an average 12.3 g/L improvement in haemoglobin within 2 weeks, but commonly caused reductions in serum phosphate (although none of these was clinically symptomatic). Parenteral iron caused elevations in hepcidin sustained to 4 weeks post‐injection. Patients stated they would be prepared to receive the treatment again. Conclusion: Rapid injection of undiluted ferric carboxymaltose is well tolerated and could provide an approach to treat patients in the ambulatory setting. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

35. Determining the Rate of Anti-PF4 Antibody Positive Results in Patients Presenting with Venous Thrombosis but a Normal Platelet Count Following ChAdOx1 Ncov-19 Astrazeneca Vaccination: An Australian Combined State Testing Centre Experience

Author

Leitinger, Emma J, Clifford, Joanne, Parker, Michael, Iacobelli, Amanda, Sung, Pauline, Chen, Vivien, Brighton, Timothy A., Lee, Christine Shu Mei, Clarke, Lisa, Malan, Erica, Kershaw, Geoffrey, Shadood, Noor, Passam, Freda H., Favaloro, Emmanuel J, Tran, Huyen A, and Chunilal, Sanjeev D

Published
2021
Full Text
View/download PDF

37. Interlaboratory validation of apixaban levels in ex vivo patient samples using a chromogenic anti‐factor Xa assay.

Author

Singh, Jasmine, Ong, Doen Ming, Ling, Victoria, Lim, Ming Sheng, Malan, Erica, Servadei, Patricia, Wallis, Andrew, Kelsey, Giles, Chunilal, Sanjeev, and Tran, Huyen

Subjects
ANTICOAGULANTS, BLOOD coagulation tests, CHROMOGENIC compounds, THROMBOEMBOLISM, DATA analysis software, DESCRIPTIVE statistics
Abstract

The article offers information on the Apixaban, a direct factor Xa inhibitor, is used in the treatment and prevention of recurrent venous thromboembolism, and prevention of stroke or systemic embolism in nonvalvular atrial fibrillation. It mentions that apixaban levels can help clinicians determine the presence of apixaban when major bleeding occurs; and also mentions the chromogenic anti‐Xa assay using apixaban-specific calibrator be used for the quantification of apixaban levels.

Published
2020
Full Text
View/download PDF

39. The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing.

Author

McQuilten, Zoe K., Higgins, Alisa M., Burns, Kelly, Chunilal, Sanjeev, Dunstan, Terri, Haysom, Helen E., Kaplan, Zane, Rushford, Kylie, Saxby, Karinna, Tahiri, Renas, Waters, Neil, and Wood, Erica M.

Abstract

Background: To accurately quantify the costs of care for patients with transfusion-dependent thalassemia (TDT), and to evaluate cost-effectiveness of new treatments, data are required on costs of regular red blood cell (RBC) transfusions. However, no previous studies have evaluated the costs of RBC transfusion specifically in chronically transfused patients.Methods and Materials: We performed a time-driven activity-based costing (TDABC) study using a health care provider perspective. This was performed over a 1-month period, capturing every step of the transfusion pathway for patients with TDT at a designated provider of specialist thalassemia services in Australia. Detailed process maps were developed to outline treatments and processes directly related to transfusion. For each process map, detailed data collection, including timing of activities, was performed multiple times to account for variation in practice. Costs associated with RBC transfusion were broken down into fixed, process, and RBC procurement costs.Results: The total per-unit cost was US$695.59 (95% confidence interval, US$694.45-US$696.73). Approximately 40% of cost was for procurement of the RBC unit, with process costs accounting for 55%. The single largest contributor to process costs was attributed to iron chelation medication (approximately 80%). In sensitivity analyses, seniority of staff, time to perform processes, and probabilities of different processes occurring did not substantially influence the RBC transfusion cost; however the number of RBC units per transfusion episode did impact the overall cost per RBC unit.Conclusions: We found significant costs associated with RBC transfusion for TDT, with the product cost contributing less than one-half of the total cost. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism.

Author

Tran, Huyen A, Gibbs, Harry, Baker, Ross, Nandurkar, Harshal, Merriman, Eileen, Curnow, Jennifer L, Young, Laura, Bennett, Ashwini, Wee, Tan Chee, Chunilal, Sanjeev D, Ward, Chris M, and Tan, Chee Wee

Abstract

Introduction: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease and, globally, more than an estimated 10 million people have it yearly. It is a chronic and recurrent disease. The symptoms of VTE are non-specific and the diagnosis should actively be sought once considered. The mainstay of VTE treatment is anticoagulation, with few patients requiring additional intervention. A working group of experts in the area recently completed an evidence-based guideline for the diagnosis and management of DVT and PE on behalf of the Thrombosis and Haemostasis Society of Australia and New Zealand (www.thanz.org.au/resources/thanz-guidelines).Main Recommendations: The diagnosis of VTE should be established with imaging; it may be excluded by the use of clinical prediction rules combined with D-dimer testing. Proximal DVT or PE caused by a major surgery or trauma that is no longer present should be treated with anticoagulant therapy for 3 months. Proximal DVT or PE that is unprovoked or associated with a transient risk factor (non-surgical) should be treated with anticoagulant therapy for 3-6 months. Proximal DVT or PE that is recurrent (two or more) and provoked by active cancer or antiphospholipid syndrome should receive extended anticoagulation. Distal DVT caused by a major provoking factor that is no longer present should be treated with anticoagulant therapy for 6 weeks. For patients continuing with extended anticoagulant therapy, either therapeutic or low dose direct oral anticoagulants can be prescribed and is preferred over warfarin in the absence of contraindications. Routine thrombophilia testing is not indicated. Thrombolysis or a suitable alternative is indicated for massive (haemodynamically unstable) PE.Changes in Management AsA Result Of the Guideline: Most patients with acute VTE should be treated with a factor Xa inhibitor and be assessed for extended anticoagulation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

42. Age‐adjusted cut‐off using the IL D‐dimer HS assay to exclude pulmonary embolism in patients presenting to emergency.

Author

Lim, Ming S., Bennett, Ashwini, and Chunilal, Sanjeev

Subjects
AGE distribution, ALGORITHMS, BIOLOGICAL assay, BLOOD vessels, COMPUTED tomography, HOSPITAL emergency services, PULMONARY embolism, DISEASE prevalence, RETROSPECTIVE studies, FIBRIN fibrinogen degradation products
Abstract

Abstract: Background/Aim: The ADJUST‐PE study showed that an age‐adjusted D‐dimer (AADD) (age years × 10 ng/mL if >50 years) combined with an unlikely pre‐test probability (PTP) can increase the proportion of older patients in whom pulmonary embolism (PE) can be safely excluded, but the IL D‐dimer HS assay was not assessed. To assess the ability of the IL D‐dimer HS assay to exclude PE using the AADD. Methods: Retrospective analysis of consecutive patients presenting with symptoms of acute PE to one of three Monash Health Emergency Departments (January 2013–January 2014) who had computed tomography pulmonary angiography. In the group with D‐dimer, efficiency (proportion of PE excluded based on a combination of unlikely PTP and negative D‐dimer) was determined using (i) current laboratory (200 ng/mL), (ii) conventional (230 ng/mL) and (iii) modified (375 ng/mL if age ≥60 years) AADD cut‐offs. Results: A total of 176 patients with D‐dimers was included (mean age = 58.5 years; 54.0% males; 71.0% age >50 years). Prevalence of PE in the overall, unlikely and likely PTP groups, was 17.0, 13.0 and 24.6% respectively. In the unlikely PTP group (115 patients), efficiency for the current, conventional, modified and AADD cut‐offs was 9.6, 24.3, 30.4 and 37.4% respectively. Conclusion: The absolute increase in efficiency of an AADD compared to conventional cut‐off using the IL D‐dimer HS assay is modest (~10%) and requires prospective validation. Modifying our cut‐off to 230 ng/mL and systematic implementation of a clinical algorithm, including D‐dimer testing and PTP, is likely a more important first step. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

43. CLINICAL CONSULTATION

Author

CHUNILAL, SANJEEV D. and GINSBERG, JEFFREY S.

Subjects
Travel -- Health aspects -- United States, Thromboembolism -- Prevention -- Health aspects, Health, Prevention, Health aspects
Abstract

Answer to a reader's question on: Travel as a risk factor for thromboembolism Is there a link between long trips and venous thromboembolism? To what extent is travel a risk [...]

Published
1999

45. Application of a strain rate gradient microfluidic device to von Willebrand's disease screening.

Author

Brazilek, Rose J., Tovar-Lopez, Francisco J., Wong, Angus K. T., Tran, Huyen, Davis, Amanda S., McFadyen, James D., Kaplan, Zane, Chunilal, Sanjeev, Jackson, Shaun P., Nandurkar, Harshal, Mitchell, Arnan, and Nesbitt, Warwick S.

Subjects
MICROFLUIDIC devices, STRAIN rate, VON Willebrand disease, BLOOD platelet aggregation, HEMODYNAMICS, DIAGNOSIS
Abstract

Von Willebrand's disease (VWD) is the most common inherited bleeding disorder caused by either quantitative or qualitative defects of von Willebrand factor (VWF). Current tests for VWD require relatively large blood volumes, have low throughput, are time-consuming, and do not incorporate the physiologically relevant effects of haemodynamic forces. We developed a microfluidic device incorporating micro-contractions that harnesses well-defined haemodynamic strain gradients to initiate platelet aggregation in citrated whole blood. The microchannel architecture has been specifically designed to allow for continuous real-time imaging of platelet aggregation dynamics. Subjects aged ≥18 years with previously diagnosed VWD or who presented for evaluation of a bleeding disorder, where the possible diagnosis included VWD, were tested. Samples were obtained for device characterization as well as for pathology-based testing. Platelet aggregation in the microfluidic device is independent of platelet amplification loops but dependent on low-level platelet activation, GPIb/IX/V and integrin αIIbβ3 engagement. Microfluidic output directly correlates with VWF antigen levels and is able to sensitively detect aggregation defects associated with VWD subtypes. Testing demonstrated a strong correlation with standard clinical laboratory-based tests. Head-to-head comparison with PFA100® demonstrated equivalent, if not improved, sensitivity for screening aggregation defects associated with VWD. This strain rate gradient microfluidic prototype has the potential to be a clinically useful, rapid and high throughput-screening tool for VWD as well as other strain-dependent platelet disorders. In addition, the microfluidic device represents a novel approach to examine the effects of high magnitude/short duration (ms) strain rate gradients on platelet function. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19.

Author

McQuilten, Zoe K., Venkatesh, Balasubramanian, Jha, Vivekanand, Roberts, Jason, Morpeth, Susan C., Totterdell, James A., McPhee, Grace M., Abraham, John, Bam, Niraj, Bandara, Methma, Bangi, Ashpak K., Barina, Lauren A., Basnet, Bhupendra K., Bhally, Hasan, Bhusal, Khema R., Bogati, Umesh, Bowen, Asha C., Burke, Andrew J., Christopher, Devasahayam J., and Chunilal, Sanjeev D.

Subjects
ENOXAPARIN, COVID-19, HOSPITAL patients, CONFIDENCE intervals, ANTICOAGULANTS, HEALTH outcome assessment, RANDOMIZED controlled trials, COMPARATIVE studies, THROMBOEMBOLISM, LOW-molecular-weight heparin, ASPIRIN, DESCRIPTIVE statistics, STATISTICAL sampling, ODDS ratio, PROBABILITY theory
Abstract

Background: Optimal thromboprophylaxis for hospitalized patients with coronavirus disease 2019 (Covid-19) is uncertain. Methods: In an open-label, adaptive platform trial, we randomly assigned hospitalized adults with Covid-19 to low-dose low-molecular-weight heparin thromboprophylaxis or intermediate-dose or low-dose plus aspirin. In response to external evidence, the aspirin intervention was discontinued and a therapeutic-dose arm added. The primary end point was death or the requirement for new organ support by day 28, analyzed with a Bayesian logistic model. Enrolment was closed as a result of operational constraints. Results: Between February 2021 and March 2022, 1574 patients were randomly assigned. Among 1526 participants included in the analysis (India, n=1273; Australia and New Zealand, n=138; and Nepal, n=115), the primary outcome occurred in 35 (5.9%) of 596 in low-dose, 25 (4.2%) of 601 in intermediate-dose, 20 (7.2%) of 279 in low-dose plus aspirin, and 7 (14%) of 50 in therapeutic-dose anticoagulation. Compared with low-dose thromboprophylaxis, the median adjusted odds ratio for the primary outcome for intermediate-dose was 0.74 (95% credible interval [CrI], 0.43 to 1.27; posterior probability of effectiveness [adjusted odds ratio<1; Pr], 86%), for low-dose plus aspirin 0.88 (95% CrI, 0.47 to 1.64; Pr, 65%), and for therapeutic-dose anticoagulation 2.22 (95% CrI, 0.77 to 6.20; Pr, 7%). Overall thrombotic and bleeding rates were 0.8% and 0.4%, respectively. There were 10 serious adverse reactions related to anticoagulation strategy, of which nine were grade 1 or 2 across study interventions and one grade 4 episode of retroperitoneal hematoma in a patient receiving intermediate-dose anticoagulation. Conclusions: In hospitalized non-critically ill adults with Covid-19, compared with low-dose, there was an 86% posterior probability that intermediate-dose, 65% posterior probability that low-dose plus aspirin, and a 7% posterior probability that therapeutic-dose anticoagulation reduced the odds of death or requirement for organ support. No treatment strategy met prespecified stopping criteria before trial closure, precluding definitive conclusions. (Funded by Australian National Health and Medical Research Council or Medical Research Future Fund Investigator and Practitioner Grants and others; ClinicalTrials.gov number, NCT04483960.) [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Diagnosis and Management of Deep Vein Thrombosis and Pulmonary Embolism in Pregnancy.

Author

Bennett, Ashwini and Chunilal, Sanjeev

Subjects
*PREGNANCY complications, *VENOUS thrombosis diagnosis, *PULMONARY embolism, *VENOUS thrombosis treatment, *DIAGNOSIS, *THERAPEUTICS
Abstract

Pregnancy-associated venous thromboembolism (PAVTE) consists of deep vein thrombosis and pulmonary embolism (PE) occurring during pregnancy or in the postpartum period. This condition is common and is a major source of morbidity in a population which is young and otherwise relatively healthy. Timely diagnosis and treatment are crucial in ensuring satisfactory patient outcomes. Diagnostic strategies for pregnancy-associated PE in particular require careful consideration of maternal and fetal risks. Low-molecular-weight heparins currently form the mainstay of treatment; however, there are uncertainties around optimal dosing of these agents in certain settings (e.g., obesity). This review discusses the diagnosis and suggested treatment of PAVTE. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

50. Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging.

Author

Wee-Shian Chan, Spencer, Frederick A., Lee, Agnes Y. Y., Chunilal, Sanjeev, Douketis, James D., Rodger, Marc, and Ginsberg, Jeffrey S.

Subjects
PREGNANCY complications, THROMBOSIS, DIAGNOSTIC ultrasonic imaging, ILIAC vein, DOPPLER ultrasonography, EMBOLISMS, DISEASE prevalence
Abstract

Background: Compression ultrasonography performed serially over a 7-day period is recommended for the diagnosis of deep vein thrombosis in symptomatic pregnant women, but whether this approach is safe is unknown. We evaluated the safety of withholding anticoagulation from pregnant women with suspected deep vein thrombosis following negative serial compression ultrasonography and iliac vein imaging. Methods: Consecutive pregnant women who presented with suspected deep vein thrombosis underwent compression ultrasonography and Doppler imaging of the iliac vein of the symptomatic leg(s). Women whose initial test results were negative underwent serial testing on 2 occasions over the next 7 days. Women not diagnosed with deep vein thrombosis were followed for a minimum of 3 months for the development of symptomatic deep vein thrombosis or pulmonary embolism. Results: In total, 221 pregnant women presented with suspected deep vein thrombosis. Deep vein thrombosis was diagnosed in 16 (7.2%) women by initial compression ultrasonography and Doppler studies; none were identified as having deep vein thrombosis on serial testing. One patient with normal serial testing had a pulmonary embolism diagnosed 7 weeks later. The overall prevalence of deep vein thrombosis was 7.7% (17/221); of these, 65% (11/17) of cases were isolated to the ilio - femoral veins and 12% (2/17) were isolated iliac deep vein thromboses. The incidence of venous thromboembolism during follow-up was 0.49% (95% confidence interval [CI] 0.09%-2.71%). The sensitivity of serial compression ultrasonography with Doppler imaging was 94.1% (95% CI 69.2%-99.7%), the negative predictive value was 99.5% (95% CI 96.9%-100%), and the negative likelihood ratio was 0.068 (95% CI 0.01-0.39). Interpretation: Serial compression ultrasonography with Doppler imaging of the iliac vein performed over a 7-day period excludes deep-vein thrombosis in symptomatic pregnant women. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results